Here are some recent pieces penned
Branching Regulatory Paths and Dead Ends in Psychedelics
April 15, 2024 | I. Glenn Cohen, Harvard Law School
The convergence of current psychedelics regulatory pathways may bring benefits and new challenges.
A Roadmap to Reimbursement for Psychedelics
April 16, 2024 | Molly Candon, University of Pennsylvania
Insurance reimbursement for psychedelic therapy is integral to treatment accessibility.
Are Psychedelics Safe Enough for Recreational Use?
April 17, 2024 | Joshua Siegel, Washington University School of Medicine in St. Louis
Policymakers should account for the relatively low risks of psychedelics use when deciding how to regulate them.
Why We Need To Talk About Psychedelic Dispensaries
April 18, 2024 | Victoria Litman, Roger Williams University School of Law
Dispensaries could fill the regulatory void for psychedelics and promote public health.
It Is High Time the U.K. Changes Psychedelics Laws
April 22, 2024 | Joanna Neill, University of Manchester
Legislators should lower regulatory hurdles impeding psilocybin assisted psychotherapy research.
A New Era of Psychedelic Medicine in Australia
April 23, 2024 | Daniel Perkins, University of Melbourne
Australia implements a new framework for regulating the medicinal use of psychedelic substances such as MDMA and psilocybin.
Read all at
